Martín-Cruz, Leticia http://orcid.org/0000-0002-2546-1183
Viñuela, Marcos
Kalograiaki, Ioanna http://orcid.org/0000-0001-7950-2334
Angelina, Alba
Oquist-Phillips, Paola http://orcid.org/0000-0003-4418-3892
Real-Arévalo, Irene
Cañada, Francisco Javier http://orcid.org/0000-0003-4462-1469
Tudela, José Ignacio
Moltó, Luis
Moreno-Sierra, Jesús
Subiza, José Luis
Palomares, Oscar
Funding for this research was provided by:
Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF-2017-84978-R, PID2020-114396RB-I00, PID2021-123781OB-C22, RTC-2015-3805-1)
Article History
Received: 12 April 2023
Revised: 20 September 2023
Accepted: 17 October 2023
First Online: 22 November 2023
Competing interests
: OP received research grants from MINECO, Ministerio de Ciencia e Innovación, Inmunotek SL, and Novartis and fees for giving scientific lectures or participation in Advisory Boards from: AstraZeneca, Pfizer, GlaxoSmithKline, Inmunotek S.L, Novartis and Sanofi-Genzyme. FJC received research grants from MINECO, Ministerio de Ciencia e Innovación and Inmunotek S.L. and fees from Inmunotek S.L. for giving scientific lectures and advice. IK and PO-P were contracted under those grants. JLS is the founder and CEO of Inmunotek SL. MV and JIT are employees of Inmunotek SL. The remaining authors declare no conflicts of interest.